

Siemens Healthcare Diagnostics GmbH, HC CEMEA CEE QT, Siemensstrasse 90, 1210 Vienna

Name Department

Telephone

Mobile

E-mail

Date

M.A. Roland Ertl HC CEMEA CEE QT

+43 51707-38274 +43 (664) 8011738274 roland.re.ertl@siemens.com

April 12th, 2017

Document Ref# VC17-04.A.OUS

Urgent Field Safety Notice: Dimension[®] EXL[™] integrated chemistry system Dimension Vista[®] System Dimension EXL TNI, Dimension Vista DIGXN, E2, FERR, PRL, TSH

Incorrect Biotin Non-Interference Units in IFUs

Dear Sirs,

Our records indicate that your facility may have received the products listed in Table 1.

Reason for Field Action

Siemens Healthcare Diagnostics has confirmed that the concentrations for Biotin listed in the Non-Interfering Substances section of the current Dimension and Dimension Vista Instructions For Use for Dimension TNI, Dimension Vista DIGXN, E2, FERR, PRL, TSH have incorrect units, and incorrectly state the level at which biotin does not interfere. In the cases of TNI, E2, FERR, PRL, and TSH, there is significant interference at the levels incorrectly stated in the current IFU. DV E2, a competitive assay, exhibits a positive bias while the other methods (sandwich assays) exhibit a negative bias. DIGXN SI units for Biotin are incorrect by a factor of 100 lower than the level at which biotin does not interfere, in the current IFU.Dimension (DM) and Dimension Vista (DV) Affected product:

Assay	Catalog Number	Siemens Material Number (SMN)	Lot Number	
DM Troponin I (TNI)	RF621	10464525	All lots (including all future lots until Instructions For Use is updated)	
DV Digoxin (DIGXN)	K6435	10488927	All lots (including all future lots until Instructions For Use is updated)	
DV Estradiol (E2)	K6463	10489099	All lots (including all future lots until Instructions For Use is updated)	
DV Ferritin (FERR)	K6440	10445136	All lots (including all future lots until Instructions For Use is updated)	
DV Prolactin (PRL)	K6462	10488398	All lots (including all future lots until Instructions For Use is updated)	
DV Thyroid Stimulating Hormone (TSH)	K6412	10445104	All lots (including all future lots until Instructions For Use is updated)	

Siemens Healthcare Diagnostics GmbH Management: Wolfgang Koeppl, Stefan Scheidler Siemensstrasse 90 1210 Vienna Austria Tel.: +43 51707 0 healthcare.siemens.com

Rechtsform: Gesellschaft mit beschraenkter Haftung; Firmensitz: Wien; Firmenbuchnummer: FN 135042 t; Firmenbuchgericht: Handelsgericht Wien; DVR: 0816540



Assay	Current Conventional Units in IFU	Current SI Units in IFU	Corrected Conventional Units	Corrected SI Units
DM EXL TNI	100 ng/mL	410 µmol/L	Correct as is	409 nmol/L
DV DIGXN	50 ng/mL	2.04 nmol/L	Correct as is	204 nmol/L
DV E2	100 ng/mL	409 µmol/L	Correct as is	409 nmol/L
DV FERR	100 ng/mL	410 µmol/L	Correct as is	409 nmol/L
DV PRL	0.2 mg/dL	8.2 mmol/L	100 ng/mL	409 nmol/L
DV TSH	500 ng/mL	2050 µmol/L	Correct as is	2050 nmol/L

Table 1. Biotin Units in Non-Interfering Table:

The corrected, Biotin conventional and SI units provided in this letter, in the Non-Interfering Table (Table 2), supersedes the information related to this section in the current IFU's for the assays listed above for Dimension and Dimension Vista products until the IFU's are updated.

Risk to Health

The probability of misinterpretation of results for the assays described above due to this issue is remote, and would be limited to the scenario where a patient taking biotin supplements in excess of the daily recommended allowance has a blood sample drawn before biotin is cleared to a level that does not interfere with laboratory testing. Mitigations include correlation to clinical history and presentation as well as to other diagnostic laboratory testing, serial testing, and/or concomitant imaging studies depending on the analyte. Siemens is not recommending a lookback as a result of this issue.

Actions to be Taken by the Customer

- Review the information contained in Table 2.
- Review this letter with your Medical Director.
- Complete and return the Field Correction Effectiveness Check Form attached to this letter within 30 days.
- If you have received any complaints of illness or adverse events associated with the products listed in Tables 1, immediately contact your local Siemens Customer Care Center or your local Siemens technical support representative.

Please retain this letter with your laboratory records, and forward this letter to those who may have received this product.

We apologize for the inconvenience this situation may cause. If you have any questions, please contact your Siemens Customer Care Center or your local Siemens technical support representative.

Sincerely yours,

Siemens Healthcare Diagnostics GmbH

i.V. Dipl. Ing. Franz Schwarz Head of RAQS Austria & SEE

i.A. Dr.ⁱⁿ Brigitte Gassner Product Manager Austria & SEE